Plexxikon
Scaffold-Based Drug Discovery
Cardio-Renal
CNS
Inflammation
Metabolic Disease
Oncology
About
Management
Board of Directors
Scientific Advisors
Pipeline
Cardio-Renal
CNS
Inflammation
Metabolic Disease
Oncology
Clinical Trials
Partners
Partnering Opportunities
Partnerships
Investors
News
Press Releases
Plexxikon in the News
Press Kit
Careers
Contact Us
Driving Directions
Press Releases
Recent Press Releases
07/14/2010
Plexxikon's Novel Agent Significantly Inhibits Activation of Key CNS Cells Associated With Alzheimer's Disease
06/06/2010
PLX4032 Phase 1 Extension Data in Colorectal Cancer Reported
04/20/2010
Plexxikon's PLX3397 Preclinical Data Demonstrate Potential of Novel, "First-in-Class" Cancer Drug
04/19/2010
Plexxikon Co-Founder Joseph Schlessinger, Ph.D., Awarded 2010 Pezcoller Foundation-AACR International Award for Cancer Research
01/08/2010
Plexxikon Announces First Patient Dosed in Phase 3 Trial
10/08/2009
Plexxikon Treats Initial Patient With First-in-Class Drug in Phase 1 Trial
09/30/2009
Plexxikon Announces First Patient Dosed in First of Two Pivotal Trials of PLX4032 for Metastatic Melanoma
09/23/2009
Plexxikon Announces Encouraging Data from Phase 1 Extension Study of PLX4032 Showing Objective Responses in Metastatic Melanoma Patients
09/10/2009
Key Data Related to Plexxikon's Lead Oncology Program PLX4032 to be Presented at ECCO15 / ESMO34 2009 Conference
06/01/2009
Plexxikon Announces PLX4032 Phase 1 Data Showing Objective Responses in Metastatic Melanoma Patients
05/15/2009
Key Data Related to Plexxikon's Lead Oncology Program PLX4032 to be Presented at ASCO 2009 Annual Meeting
03/19/2009
Plexxikon Receives Key Patents on Novel Compounds for Multiple Programs
01/08/2009
Plexxikon and Roche Enter Second Partnership to Develop PLX5568 for Polycystic Kidney Disease
Archived Press Releases